退市5年，龙力生物案判决出炉！1618名投资者获赔超2.7亿元

Core Viewpoint - The court ruling on the securities fraud liability dispute involving Shandong Longli Biological Technology Co., Ltd. (Longli Bio) has concluded after five years post-delisting, with 1,618 investors claiming a total of 274 million yuan in investment loss and additional legal fees [1][2][3]. Group 1: Court Ruling and Financial Implications - The Jinan Intermediate People's Court ruled that the 1,618 plaintiffs are entitled to a total of 274 million yuan in investment loss claims and 809,000 yuan in legal fees, with five representative plaintiffs also entitled to 80,600 yuan in notification fees [1][3]. - Defendant Cheng Shaobo is jointly liable for the debts owed to the plaintiffs, while other defendants will bear joint liability within a certain proportion [1][3]. - Guolian Minsheng Securities is liable for 5% of the plaintiffs' losses, while Lixin Accounting Firm is liable for 30% of the losses [1][3]. Group 2: Background and Context - Longli Bio was listed on the Shenzhen Stock Exchange on July 28, 2011, and was once known as the "first stock of biofuels" [2]. - The company was placed under risk warning in January 2018 and was officially delisted in July 2020 due to significant fraudulent activities, including profit inflation from 2015 to mid-2017 [2][3]. - The China Securities Regulatory Commission (CSRC) previously identified Longli Bio for systematic fraud, resulting in fines totaling 3.38 million yuan against 18 responsible parties [2]. Group 3: Legal Proceedings and Future Outlook - The collective lawsuit initiated by over 1,600 investors against Longli Bio and associated parties has taken three years to reach a verdict [3]. - Following the ruling, Guolian Minsheng announced the potential for appeals, indicating that the final judgment remains uncertain [4]. - The company maintains a stable financial status, asserting that the lawsuit's financial implications will not significantly affect its current or future profits [4].